Zentalis reports survival data from azenosertib ovarian cancer study
Zentalis Pharmaceuticals has reported interim overall survival results from the DENALI Part 1b study evaluating azenosertib in patients with platinum-resistant ovarian cancer.
The post Zentalis reports survival data from azenosertib ovarian cancer study appeared first on Clinical Trials Arena .